These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34359621)

  • 1. Immunotherapy in Glioblastoma: A Clinical Perspective.
    Desbaillets N; Hottinger AF
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects.
    Chowdhury S; Bappy MH; Clocchiatti-Tuozzo S; Cheeti S; Chowdhury S; Patel V
    Cureus; 2021 Dec; 13(12):e20604. PubMed ID: 35103180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.
    Montoya ML; Kasahara N; Okada H
    Neurooncol Pract; 2020 Oct; 7(5):465-476. PubMed ID: 33014387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions.
    Khaddour K; Johanns TM; Ansstas G
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33202642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in glioblastoma treatment: Current state and future prospects.
    Rocha Pinheiro SL; Lemos FFB; Marques HS; Silva Luz M; de Oliveira Silva LG; Faria Souza Mendes Dos Santos C; da Costa Evangelista K; Calmon MS; Sande Loureiro M; Freire de Melo F
    World J Clin Oncol; 2023 Apr; 14(4):138-159. PubMed ID: 37124134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy Resistance in Glioblastoma.
    Wang EJ; Chen JS; Jain S; Morshed RA; Haddad AF; Gill S; Beniwal AS; Aghi MK
    Front Genet; 2021; 12():750675. PubMed ID: 34976006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Checkpoint Inhibitors in Glioblastoma.
    Desai K; Hubben A; Ahluwalia M
    Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.